Vaccine Damage Payments Act 1979

Debate between Maria Caulfield and Andrew Bridgen

Friday 24th March 2023 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Maria Caulfield)]

I thank my hon. Friend the Member for Christchurch (Sir Christopher Chope) for securing this important debate. I met him earlier to listen to many of his concerns on the issue. We know that, unfortunately, there have been some rare instances in which individuals have suffered possible harm following a covid-19 vaccination. Of course, my sympathy goes out to them and their families. The Government are keen to help those who feel that they have been affected by this issue; that is why I have agreed to meet the all-party parliamentary group and Members from across the House who have concerns on the issue.

The vaccine damage payment is a one-off, tax-free payment to individuals who have been found, on the balance of probabilities, to have been harmed by any vaccine, including covid vaccines. It was established over 40 years ago, and provides support to those who have experienced severe disablement that could have been, on the balance of probabilities, caused by a vaccine against one of the conditions listed in the legislation. The NHS Business Services Authority took over the scheme in November 2021 to try to improve the process, and speed up the response to and assessment of applicants. Assessments are done on a case-by-case basis by experienced, independent medical assessors, who have undertaken specialised training in vaccine damage and disability assessment. That is partly why the process can take so long. I will touch on the other reasons.

My hon. Friend raised concern about the payment of £120,000. I have listened to his point; indeed, it was raised at Prime Minister’s questions this week. It is important to note that the amount is a one-off, lump-sum payment. It is not designed to cover lifetime costs for those impacted. It is in addition to other support packages, such as statutory sick pay, universal credit, employment and support allowance, attendance allowance and personal independence payments. Also, it has increased since the scheme was put in place; it was just £10,000 in 1979. The amount has been raised several times, the current level having been set in 2007. The amount will be kept under review. I will take away the points that my hon. Friend made in this debate and in our meeting beforehand. As he is aware, a successful claim under the scheme does not preclude individuals from bringing a claim for damages through the courts. There are a number of claims under way, and I cannot comment on those specifically.

My hon. Friend also touched on the 60% disability threshold, which was lowered from the initial 80% threshold in 2002, to remain aligned with the definition of severe disablement set out by the industrial injuries disablement benefit, so that there is consistency across the board. Only 67 of more than 4,000 rejected claims were rejected as not being eligible for the scheme, on the basis of not meeting the 60% disability threshold. Claims are usually rejected for other reasons, so the threshold is not affecting a significant number of claims. We do not see the threshold as a big barrier to those who want to make a claim but, of course, we will keep it under review as the scheme progresses.

The BSA took over the scheme in November 2021, because we found that claims were taking a while. A key issue was getting access to patient records. NHS BSA has done a huge amount of work in that short space of time. On average, it is now taking around six months to process a claim, whereas it was previously taking significantly longer. The BSA has put in place digital modernisation processes that allow for a quicker, easier and faster application process. It has also put in place a strategic research agreement so that patients who make a claim can give consent on application, which enables the team to request the patient’s records from hospitals, GPs and other organisations to be able to determine the claim.

While the new process has bedded in, NHS BSA has introduced quality standards. Although everyone has the right of appeal if their claim is rejected, we want to get it right first time. Making sure those quality assurance processes are in place means that we determine eligible claims first time. The last thing we want is for people to have to appeal because the initial assessment was not correct.

We have also increased staff numbers. The scheme had four members of staff when it sat with the Department for Work and Pensions but, because of the sheer number of claims, more than 80 people are now taking part in the process to assess claims quicker.

I hope I have been able to reassure my hon. Friend, but I will touch on some of the issues around vaccine safety in my remaining couple of minutes. I recognise that he has concerns about the vaccine, and that is why we have instigated further research. There is £110 million going into the National Institute for Health and Care Research to fund covid vaccine research, and that includes vaccine safety and the robust monitoring of adverse events. We have also allocated £1.6 million to researchers at the University of Liverpool, to understand the rare condition of blood clotting with low platelets following vaccination.

[Andrew Bridgen]

Will the Minister answer the question I asked in the Chamber last week? Why has the Medicines and Healthcare products Regulatory Agency decided to stop publishing updates to the yellow card scheme relating to covid-19 injuries?

[Maria Caulfield]

I am happy to write to the MHRA to get a response for the hon. Gentleman on that point, but I hope he will be reassured that the Government are investing in research on vaccine safety both at the University of Liverpool and at the National Institute for Health and Care Research, because we want to reassure people about the safety of vaccines.

On the VDPS, I want to reassure those making claims that the Government want to support them through the process. I have not touched on it much in my response, but I am keen to reassure those who feel they have suffered and who are struggling to get healthcare for their symptoms that we are looking at this.

Oral Answers to Questions

Debate between Maria Caulfield and Andrew Bridgen

Tuesday 24th January 2023 Commons Chamber

[Maria Caulfield]

We are seeing an increase in excess deaths in this country, but we are also seeing that in Wales, in Scotland, in Northern Ireland and across Europe. There is a range of factors. As we saw, there was an increase in December in the number of people being admitted with flu, covid and other healthcare conditions. That was seen not just in this country, but across Europe.

[Andrew Bridgen (North West Leicestershire) (Ind)]

The Office for National Statistics has not issued mortality data by vaccination status since 31 May last year. Will the Minister confirm that her Department has collected that data for the rest of 2022 and inform the House when it will be published?

[Maria Caulfield]

I am happy to write to the hon. Gentleman with that information. However, I must be clear that we planned for an increase in admissions this winter. That is why we got on and delivered on our plans for 7,000 extra beds, and why we brought forward our flu and covid vaccination programme and lowered the age of eligibility. There are a number of factors, and they are the same factors that have driven excess deaths across the United Kingdom and across Europe.

Vaccines: Potential Harms

Debate between Maria Caulfield and Andrew Bridgen

Tuesday 13th December 2022 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Maria Caulfield)]

I thank my hon. Friend the Member for North West Leicestershire (Andrew Bridgen) for securing the debate. It is important that all Members get to discuss and debate such issues, and they are entitled to their opinion.

I have to say that I strongly disagree with my hon. Friend, not only in the content of his speech, but in the way he derided doctors, scientists and nurses. Many of us worked through the pandemic and saw at first hand the devastation that covid caused. There is no doubt in my mind that, despite the personal protective equipment, social distancing and infection control, the thing that made the biggest difference in combating covid was the introduction of the vaccine.

Safe and effective vaccines have underpinned our strategy for living with covid. Covid has not gone away, but we are living with it in a way that was not possible this time last year. Vaccines have saved thousands of lives, reduced the pressure on the NHS, and allowed the economy and society to reopen, not just in this country but in countries across the world. In countries with lower vaccination rates, their ability to open up, move on and live with covid was reduced.

Across the piece—not just for covid—vaccines remain our biggest line of defence, particularly during a challenging winter period. We see with our seasonal flu vaccine roll-out and our covid programme that getting the most vulnerable people vaccinated—

[Andrew Bridgen]

Will the Minister give way on that point?

[Maria Caulfield]

I will not. I have just three minutes to respond to the many points that my hon. Friend made.

It is important to put on the record that all the vaccines used in the UK are safe, and we have some of the highest safety standards in the world, with the MHRA globally recognised for requiring high standards of safety. I have worked in clinical research, and I can say categorically that the data is not hidden from the public or the MHRA; it is inspected rigorously and can be reinspected at any time.

Each of our covid vaccine candidates is assessed by a team of scientists and clinicians on a case-by-case basis, and it is only once a potential vaccine has met robust standards of effectiveness, safety and quality that it is approved for use. That is the case for all medicines, not just covid vaccines. Extensive data shows that the vaccine is safe and highly effective in reducing the deaths that we sadly saw during the pandemic. That does not end when the vaccine is approved; surveillance of vaccines continues, as it does with any medicine, and any adverse reaction is recorded on a regular basis. That does not stop following approval.

My hon. Friend talked about the yellow card reports. Those have been in place for many years. Anyone who has a side effect from any medicine can make a yellow card report. When I was first starting out in nursing, that was a physical yellow card; it is now online. Anyone can submit any suspected adverse drug reaction. The MHRA will collate and review them, and it has in the past gone on to suspend the licence of a medicine if it has concerns. That is something that it can do for any vaccine, including any covid vaccine.

The nature of the yellow card reporting system means that some reported events are not always proven side effects. A side effect can be reported; the MHRA will then go and look to see whether it is actually related to that medicine, and there is a list of probabilities of how likely it is that the side effect is related to that medicine. There is comprehensive surveillance to alert us to any unforeseen adverse reactions to vaccines and to enable us to act swiftly when required.

We know that there are some circumstances where individuals have sadly experienced harm with a possible link to a vaccination. I recognise how difficult that is for those individuals and their families. We have put measures in place to monitor any possible side effects and to commission further research that will help us better understand how to diagnose and treat those who have suffered or continue to suffer any ill effects from a covid-19 vaccine. That is the case for any medicine—even with a simple medicine such as paracetamol, people can get side effects—and that is why every medicine that is prescribed and dispensed has a patient safety information sheet listing the most likely side effects and encouraging people to report any that may not be included.

--- Later in debate ---

[Maria Caulfield]

I will write to my hon. Friend with an update on that report. It was touched on that the MHRA has licensed the vaccine for babies, but that has not yet been approved by the JCVI, so that is just a licence rather than a recommendation to roll out. However, I am happy to send him the details of that report.

I want to put on the record that the covid vaccines have saved tens of thousands of lives and prevented hundreds of thousands of people from being hospitalised. I completely disagree with my hon. Friend the Member for North West Leicestershire that there is a whole conspiracy of doctors, nurses and scientists—they have done nothing but work hard to get us through the pandemic.

[Andrew Bridgen]

rose—

[Maria Caulfield]

I will give way for one brief point.

[Andrew Bridgen]

I thank the Minister for giving way on that important point. The claims about the number of lives saved worldwide by the vaccination are sponsored by vested interests. The modelling is the lowest form of scientific evidence—in fact, it is more science fiction than science fact.

[Maria Caulfield]

I completely disagree. I worked on the covid wards with patients who were dying from that virus. We had infection control measures, antibiotics, dexamethasone—a steroid—and every known facility available, and the only thing that made a difference was when those vaccines were introduced. They do not necessary stop people from getting the virus, but they certainly reduce its intensity and the likelihood of someone dying from it.

I completely debunk the conspiracy theories about a whole group of people benefiting financially from the roll-out of the vaccine and would gently say to my hon. Friend that if he has evidence, there are mechanisms in place for raising concerns, as we have seen with other drugs. Only today, I was before the Health and Social Care Committee talking about sodium valproate—we also had an Adjournment debate on that last week—where there are genuine safety concerns. The MHRA is taking that extremely seriously. It is not worried about pharma concerns; its first priority is patients, and it is exactly the same with the covid vaccine. So if there is evidence—I am not saying that there is not—it absolutely must go through the proper channels so that it can be evaluated.

We have launched a nationwide campaign to encourage people to come forward this winter to get their booster. I recommend that people do that safe in the knowledge that the vaccine is safe for people to have.

Question put and agreed to.